Attorney Docket No. 00826-03 Patent Application Serial No. 10/530,805 Response to 4/26/07 Restriction Requirement

Remarks

Examiner has requested applicants to elect one of the following groups of claims:

Group I, Claims 1-23 and 25-26; drawn to a product: a composition comprising a glutamine-bearing compound; and a first method: a method of enhancing the absorption of a

Group II, Claims 24 and 27-30; drawn to a second method of reducing the emergence of antiretroviral drug resistance in a chronic wasting patient.

The Examiner further alleges that the claims are directed to more than one species:

Different amino acid sequences: disclosed in claims 7-10, 16-19 and 30;

Antiretroviral drug: protease inhibitor or reverse transcriptase inhibitor,

zidovudine, lamivudine, stabudine, didanosine, efavirenz, nevirapine or nelfinavir; and

Protease cleavage site: trypsin, chymotrypsin, Factor Xa, or TEV.

Response to Restriction Requirement

pharmaceutical agent administered orally to a mammal.

Applicants hereby provisionally elect Group I (claims 1-23 and 25-26), drawn to a product: a composition comprising a glutamine-bearing compound; and a first method: a method of enhancing the absorption of a pharmaceutical agent administered orally to a mammal.

Response to Species Election Requirement

Regarding the amino acid sequences, Applicants hereby provisionally elect <u>ALA(GLN)n</u>.

Regarding the antiretroviral drugs, Applicants hereby provisionally elect <u>protease</u> inhibitor, nelfinavir.

Regarding the protease cleavage site: Applicants hereby provisionally elect trypsin.

Attorney Docket No. 00826-03 Patent Application Serial No. 10/530,805 Response to 4/26/07 Restriction Requirement

Conclusion

If the Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (434) 243-6103.

Respectfully submitted,

Date: June 22, 2007

Rodney L. Sparks

Registration No. 53,625

University of Virginia Patent Foundation

250 West Main Street, Suite 300

Charlottesville, VA 22902

Telephone: (434) 243-6103

Fax: (434) 924-2493